Actively Recruiting
Open-Label First-in-Human Study of GEN3018 for Relapsed or Refractory Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome
Led by Genmab · Updated on 2026-11-04
78
Participants Needed
9
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and appropriate dosing of GEN3018, an antibody drug, in people with relapsed or refractory acute myeloid leukemia RR AML or higher-risk myelodysplastic syndrome RR HR-MDS. This first-in-human Phase 1 trial aims to assess how well participants tolerate GEN3018, study its behavior in the body, and observe initial anti-tumor effects. The trial is divided into two parts Dose Escalation to find a safe dose and Dose Refinement to further study the chosen doses.
CONDITIONS
Brief Title
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Research Team
G
Genmab Trial Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here